GlassScriptPhysician profile
Mangesh B Patel
NPI 1194781443
$5,454.62
in general payments reported to CMS, 2019-2025
18 companies · $15.14 in 2025
The $15.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,678 · 2020: $972 · 2021: $1,689 · 2022: $645 · 2023: $340 · 2024: $117 · 2025: $15.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,148.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,132.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $376.53 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $323.06 | 2019-2022 | |
| Novo Nordisk INC | $298.15 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $166.89 | 2019-2021 | |
| Intuity Medical INC | $156.43 | 2022 | |
| Abbvie INC. | $155.80 | 2021 | |
| Pfizer INC. | $126.40 | 2021-2023 | |
| Boston Scientific Corporation | $124.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.79 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $79.11 | 2019-2021 | |
| Emergent Biosolutions INC. | $56.96 | 2019 | |
| Amgen INC. | $56.83 | 2023 | Repatha, Otezla |
| Grt US Holding, INC. | $53.75 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $53.03 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $24.80 | 2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $23.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mangesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.